Immunomodulation of experimental allergic encephalomyelitis by cinnamon metabolite sodium benzoate

• Published in: Immunopharmacology and immunotoxicology Vol. 33; no. 4; pp. 586 - 593
• Main Author: Pahan, Kalipada
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 01.12.2011; Taylor & Francis
• Subjects: adaptive immunity; Animal models; Animals; Cell activation; Cell Communication - drug effects; Cell migration; Cell Movement - drug effects; Cell Movement - immunology; Central nervous system; Children; cinnamon; Demyelinating diseases; Drugs; EAE; Encephalomyelitis, Autoimmune, Experimental - drug therapy; Encephalomyelitis, Autoimmune, Experimental - immunology; Encephalomyelitis, Autoimmune, Experimental - pathology; Experimental allergic encephalomyelitis; Food additives; Food Preservatives - therapeutic use; glial activation; Glial cells; Humans; Immune response; Immunologic Factors - therapeutic use; Immunomodulation; Immunoregulation; Immunosuppressive agents; Inflammation; Inflammation - drug therapy; Inflammation - immunology; Inflammation - pathology; Inflammatory diseases; innate immunity; Lymphocytes T; Metabolites; Mice; microbicides; Multiple sclerosis; Multiple Sclerosis - drug therapy; Multiple Sclerosis - immunology; Multiple Sclerosis - pathology; Neuroglia - immunology; Neuroglia - pathology; Neuroimmunology; neuroinflammation; Signal transduction; Signal Transduction - drug effects; Signal Transduction - immunology; Sodium benzoate; Sodium Benzoate - therapeutic use; T-Lymphocytes, Helper-Inducer - immunology; T-Lymphocytes, Helper-Inducer - pathology; Urea

Experimental allergic encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS), the most common human demyelinating disease of the central nervous system. Sodium benzoate (NaB), a metabolite of cinnamon and a FDA-approved drug against urea cycle disorders in children, is a widely used f...